IL33 and coinfection: In this way, HIV-induced production of IL-33, protective for HIV-1 patients under highly active antiretroviral therapy, appeared to be detrimental for naïve HIV-1/TB coinfected patients, contributing to HIV-1 persistence and tissue damage in the context of HIV/TB coinfection.